MD Biosciences Blog

We are happy to announce that we have merged with MLM Medical Labs ("MLM"), a specialized laboratory dedicated to clinical trials headquartered in Germany. With our strong reputation for scientific expertise in immunology and immunological biomarkers and distinguished approach to customer care, our team is looking forward to joining the MLM family, and providing a comprehensive menu of preclinical and clinical services to an extended client base. 

MD Biosciences' life science research products manufacturing and distribution businesses in Switzerland and the US, and MD Biosciences' neurology business focused on preclinical and translational research in neurology in Israel and the US, are not part of this transaction. 

The addition of MD Biosciences follows the acquisition of CirQuest Labs in Memphis, TN earlier this summer, further expanding MLM's geographic reach. The integration of the three organizations will occur in the coming few months to align the operations and quality systems, offering customers access to MLM services in both the United States and Europe. With a stronger and larger global team, "we will have the scale and capacity to support all stages of product development", says Stephan Voswinkel, Managing Director of MLM.

"Joining the growing MLM family is the next step in the evolution of MD Biosciences, Inc., providing an expanded geographic reach in immunology and biomarker testing services. This opens the opportunity to serve MD Biosciences' growing roster of customers with their needs in Europe, the US and with the combined strength of MLM and CirQuest", commented Eddie Moradian, CEO of MD Biosciences.

MLM global services will include: 

• expertise in pre-clinical and clinical research across various therapeutic areas including inflammation, autoimmune, metabolism and oncology
• full-service histopathology lab including immunohistochemistry and digital image analysis 
• specialized biomarker testing
• clinical chemistry
• analyses of drug compounds
• molecular diagnostics 

We look forward to continuing to serve you with an expanded menu of capabilities, supporting all stages of research. To learn more about MLM Medical Labs, visit the website here. 

We are happy to announce that we have established MD Biosciences Neuro, LLC. in Cambridge, Massachusetts to expand our work and collaborations in the United States. Our team, led by Chief Scientific Officer, Sigal Meilin, is looking forward to developing close partnerships with you and continuing to advance the field of neurology and pain research.
With a multifaceted approach to assessment of neurological diseases, specializations include pain-related work, neurodegenerative diseases including Parkinson's, neuro-inflammatory diseases such as Multiple Sclerosis (MS), and capabilities in stroke and cerebral ischemia. Preclinical models are complimented by in house histology, biomarker analysis and electrophysiology capabilities. Finally, our unique porcine models share a high degree of similarity to humans, thus offering greater clinical efficacy that serve to augment and accelerate your program towards their next objectives and milestones.

Please contact us with any questions about our services, capabilities, and customizable study design options.

We are happy to announce that we have established MD Biosciences Bioproducts, LLC. in Oakdale, Minnesota to expand our work and collaborations worldwide. Our team is dedicated to the development, manufacturing and distribution of life science research products suited for inflammatory and autoimmune diseases, neurology, oncology, pain, and metabolism.

It is our goal to collaborate with pharmaceutical, biotech, academic and government communities to provide you with the tools needed to optimize your research process enabling you to reach your objectives faster. We offer antibodies, reagents and assays for use in various therapeutic areas of research.

                                       Please contact us with any questions about our products and capabilities. 

Zika Virus Test Update: Saint Paul, MN March 10, 2016

MD Biosciences announces that it will proceed with the Zika test services following clarification with the FDA regarding any pre-market approval requirements pertaining to this assay. Testing services will not be offered pending this clarification.

Saint Paul, MN, USA - February 29, 2016, - MD Biosciences, Inc. (mdbiosciences.com) Clinical and Diagnostics Services Laboratory announces the release of its rapid assay to detect the virus in human blood and urine samples. The nucleic acid test can be performed in a few hours in blood, plasma, serum or urine samples. The test is specific for the Zika virus and was shown not to cross react with other infectious viruses such as Dengue, West Nile or Chikunguya. The laboratory developed test is available immediately

The World Health Organization stated that the spread of the mosquito-borne virus will grow explosively throughout the Americas. According to the CDC, the virus has also been shown to be transmitted through sexual contact. Upwards of four million infections are expected in the region. Close to 80% of infections are asymptomatic while others suffer from fever, rash, joint aches and other hallmarks. A steep increase in birth defects and Guillain-Barre syndrome has correlated to the spread of the virus. The explosive spread of the virus, along with major crowd and traveller-related events such as this year’s Olympic Games in Brazil, have underscored the need for steps in fighting the spread of the virus, including the ability to rapidly and specifically identify the infection.

Eddie Moradian, Chief Executive Officer at MD Biosciences, stated, “We are extremely proud of our CLIA diagnostics laboratory’s ability to provide a reliable, accurate and rapid method of testing for Zika virus. This demonstrates our commitment in placing our expertise, knowledge and infrastructure for the betterment of health, in the US and throughout the world, whether through the development of more advanced diagnostics or by advancing newer, better and more efficient therapies."

About MD Biosciences

MD Biosciences is a leading provider of clinical and preclinical services with over 25 years of experience in the clinical diagnostics and preclinical research areas. Services are provided for cancer, inflammatory, metabolic and neurological diseases. MD Biosciences laboratories provide extensive experience in working with biomarkers and developing validated laboratory assays. MD Biosciences operates through its facilities and laboratories in the United States, Switzerland and Israel.

Located in Saint Paul, MN, MD Biosciences' Clinical and Diagnostics Services Laboratory is a CLIA accredited laboratory for high complexity testing. All testing is performed under stringent guidelines in state of the art laboratories. Other services include clinically relevant tests for genetic markers of diseases including various cancers.

Inquiries may be directed to: Susan Belzer, Vice President, MD Biosciences Clinical Diagnostics Laboratory

by e-mail: clinlab@mdbiosciences.com

by telephone to 1-888-USMDBIO (1-888-876-3246) or (651-641-1770).